MagForce AG Supports World Brain Tumor Day 2016 and Announces its Attendance at 67th Annual Meeting of the German Society of Neurosurgery

Berlin, Germany and Nevada, USA, June 8, 2016 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, supports today’s World Brain Tumor Day and acknowledges the global initiative, which was introduced by the German Brain Tumor Association (Deutsche Hirntumorhilfe e.V.) in 2000 to raise awareness for brain tumors and its devastating impact on patients’ and their caregivers’ lives.

In addition, MagForce announces its presence at the 67th Annual Meeting of the German Society of Neurosurgery (Deutsche Gesellschaft für Neurochirurgie, DGNC) from June 12-15, 2016 in Frankfurt, Germany. The event is one of the biggest conferences for the neuro-surgical community in Germany and dedicated to large-scale scientific exchange with neurosurgery key opinion leaders. MagForce will be represented with a booth (Hall C3, Booth #05) from June 13 to 15 and will be available for questions regarding its NanoTherm™ therapy for the treatment of glioblastoma and other brain tumors.

About the World Brain Tumor Day

This commemoration day was initialised by the Deutsche Hirntumorhilfe e.V. (German Brain Tumor Association) in 2000. Because brain tumors occur rather seldom in comparison to other cancers, they are little-noticed by the public. With the aim of directing public attention to the situation of brain tumor patients and appealing for solidarity with patients and their dependants, the World Brain Tumor Day takes place every year on June 8th. It is also a reminder directed at the responsible persons in the fields of politics and economy to assume their social responsibility. Active support of research and an increased interdisciplinary collaboration are the ways to develop new therapies and improve the chances of healing. Until that, it is essential to campaign together to advance the quality of life of patients, to give hope and show solidarity – it is essential to send a signal.

Role of NanoTherm™ Therapy in the Treatment of Brain Tumors

NanoTherm™ therapy is an intratumoral thermotherapy which aims to help patients with brain tumors. It can be used as a monotherapy or in combination with radiotherapy and/or chemotherapy to enhance their effectiveness.

With NanoTherm™ Therapy, the magnetic fluid injected into a tumor is heated through a very fast alternating magnetic field. Through the heat, tumor cells are either destroyed or sensitized for additional therapies such as radiotherapy and/or chemotherapy; thus, the efficacy of the additional
therapies is improved.

NanoTherm™ therapy was already clinically tested on approximately 90 patients with brain tumors and about 80 patients with other tumors such as pancreatic, prostate or esophageal cancer.

MagForce AG has CE mark (European Certification) in Germany and in the EU 28 to treat brain tumors with NanoTherm™ Therapy.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm™, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com.
Get to know our Technology: [video](You Tube)
Stay informed and subscribe to our [mailing list].

For meeting arrangements or any further questions, please contact us at:

**Patient Advocacy**
Dr. Katarzyna Zarychta
+49 30 95 477 95-66
kzarychta@magforce.com

**Medical Liaison**
Dr. Ulrike Boettcher
+49 89 95 477 95-64
uboettcher@magforce.com

**Media & Investors**
Barbara v. Frankenberg
+49 30 30 83 80-77
bfrankenberg@magforce.com

Disclaimer
This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.